Joyce Cheung, Head of Commercialization
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the fastest growing cause of cancer-related deaths. HCC is a complex disease, with at least eight different subtypes identified and nearly 20 known biological pathways involved. This means it requires an equally complex assay to fully capture the heterogeneity of the cancer signal, which is exactly what Helio Genomics set out to achieve.
HelioLiver is a multi-analyte blood test that analyzes cell-free DNA (cfDNA) methylation patterns and protein markers for the detection of HCC. The efficacy of this test is certainly life-saving. The test is anticipated to improve liver cancer survival rates by detecting malignancies earlier, when curative treatment is available. In fact, according to Cancer Research UK, the 10-year survival rate for some cancers is more than 90% for those diagnosed with stage I, compared with 5% for those diagnosed with stage IV.
Helio’s technology platform that backs HelioLiver, ECLIPSE, uses next-generation sequencing to identify unique biomarkers that can verifiably indicate if a cancer is present. ECLIPSE ensures more useful data can be extracted from each sample with higher quality signals of cancer, as opposed to traditional methods where the DNA can be easily damaged. Additionally, Helio’s integrative multi-modal and multi-omics platform allows for the flexibility to engage in all stages of a cancer patient’s journey—including disease monitoring, treatment guidance, and treatment response, underlining the company’s approach to provide comprehensive solutions for patients. Furthermore, Helio aims to bring together innovation and breakthrough technology to detect the majority of cancers in early stages and reverse the proliferation of this deadly disease with their innovative HelioLiver platform as a template.